Avis to Participate in '2025 American and Canadian Pathology Association'

AIVIS Inc. (CEO Daehong Lee) announced on the 21st that it will present four of the latest research results utilizing artificial intelligence (AI) in pathology solutions at the '2025 UNITED STATES AND CANADIAN ACADEMY OF PATHOLOGY (USCAP 2025)' to be held at the Boston Convention Center from the 22nd to the 27th.

USCAP is the largest pathology academic event in North America with over 100 years of history, where pathologists and industry professionals from around the world participate and share cutting-edge research results. This presentation will introduce cases of applying AI technology to various types of cancer, including thyroid cancer, urothelial cancer, and renal pathology.

In the thyroid cancer study, two results will be announced that analyzed core needle biopsy slide images and classified benign and malignant with high accuracy. In particular, the research results utilizing tissue outline information achieved an average AUC of 94.72% and F1-score of 89.18%, which is a 5-10% performance improvement over the existing ones. In both studies, the attention heatmap generated by the algorithm showed a high degree of agreement with the actual pathologist interpretation area, proving its potential for use in clinical settings.

In the field of invasive urothelial carcinoma, meaningful results on prognosis prediction are also announced. Avis predicted muscle invasion with 80% accuracy using its own AI model, and also identified the risk of recurrence with 71.43% accuracy. Previously, it was difficult to accurately determine the depth of invasion, but it is expected that AI techniques will be able to provide substantial assistance in pathologists' treatment decisions by precisely interpreting pathological tissues.

In the field of renal pathology, a virtual staining technology that automatically converts H&E images into special staining images using generative artificial intelligence is introduced. In this study, PAS, AFOG, and PM staining images were synthesized, and the similarity was recorded at the level of 0.72 to 0.87, proving that structural information similar to actual staining can be reproduced.

What is noteworthy in this presentation is the function that AI automatically analyzes digital pathology images and highlights key areas, and the system that helps shorten the time in the diagnosis process while not missing important information. In particular, some studies have demonstrated virtual staining (a technology that digitally implements various staining images), which is evaluated to have the potential to save time and cost in the pathology diagnosis process while maintaining high accuracy.

Avis has completed the introduction and PoC of digital pathology solutions in cooperation with about 20 major domestic hospitals, and is supporting accurate cancer tissue analysis and biomarker quantification through 'Quanti IHC', which has obtained approval from the Ministry of Food and Drug Safety (MFDS). In particular, it is conducting AI pathology research in the fields of companion diagnostics (CDx) and new drug development in cooperation with global medical device company Philips and pharmaceutical company AstraZeneca, and is also actively expanding into overseas markets, centered on ASEAN.

Lee Dae-hong, CEO of Avis, emphasized, “USCAP is one of the most authoritative academic conferences in the field of pathology,” and “Through these four achievements, we hope to inform the global pathology community of Avis’s pathology AI technology competitiveness and contribute to advancing the era of precision medicine.”